MSTT1041A

DRUG4 trials

Sponsors

Hoffmann-La Roche, University of Leicester, Genentech, Inc.

Conditions

AsthmaAtopic DermatitisCOPD ExacerbationCOVID-19 Pneumonia

Phase 2

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

CompletedNCT02918019

Hoffmann-La RocheAsthma

Start: 2016-09-20End: 2019-07-26Updated: 2022-12-28

Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)

CompletedNCT03615040

University of LeicesterCOPD Exacerbation

Start: 2018-10-11End: 2020-12-31Updated: 2022-06-21

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

CompletedNCT03747575

Genentech, Inc.Atopic Dermatitis

Start: 2019-02-06End: 2020-05-05Updated: 2023-05-06

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia

CompletedNCT04386616

Genentech, Inc.COVID-19 Pneumonia

Start: 2020-06-02End: 2021-02-12Updated: 2022-01-10

Related Papers

Serum Soluble ST2 (sST2) is Associated With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations and Enhanced Treatment Response to Astegolimab (Anti-ST2)

American Journal of Respiratory and Critical Care Medicine2025-05-01

Effect of anti-ST2 on blood leukocyte and serum protein levels: insight from a phase IIa, placebo-controlled trial of astegolimab (COPD-ST2OP).

2023-09-09

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

ERJ Open Research2023-08-0910 citations

Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.

2022-03-2499 citations